SEC Form 4 · accession 0001214659-17-005694
Anthera Pharmaceuticals Inc · ANTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Craig Thompson
Officer — President & CEO · Director
Period of report
Sep 20, 2017
Accepted (ET)
Sep 20, 2017 · 7:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001316175
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Sep 20, 2017 | P | 8,550 | $1.32 | A | 19,848 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person acquired the shares in the open market at a cost of $1.32 per share.